此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Individualized Brain Stimulation for Irritable Bowel Syndrome With Depressive Symptoms

Effects of Individualized Resting-State fMRI-Guided Intermittent Theta-Burst Stimulation on Depressive and Gastrointestinal Symptoms in Patients With Irritable Bowel Syndrome: A Randomized, Double-Blind, Sham-Controlled Trial

This randomized, double-blind, sham-controlled trial aims to evaluate the effects of individualized intermittent theta-burst stimulation (iTBS) on depressive and gastrointestinal symptoms in patients with irritable bowel syndrome (IBS) and depressive symptoms.

A total of 60 eligible participants will be randomly assigned in a 1:1 ratio to active or sham stimulation. Individualized stimulation targets within the left dorsolateral prefrontal cortex (DLPFC) will be identified using resting-state functional magnetic resonance imaging (fMRI).

Participants will receive 10 stimulation sessions over two weeks. Clinical assessments and multimodal brain MRI will be performed at baseline and at the end of Week 2. The primary outcome will be the change in depressive symptom severity measured by the 17-item Hamilton Depression Rating Scale (HAMD-17).

An optional ancillary study involving paired stool sample collection at baseline and Week 2 is planned to support future exploratory investigations of gut microbiota and its associations with clinical symptoms and brain network characteristics. This ancillary component will be implemented only after the relevant ethics approval and additional informed consent have been obtained.

研究概览

研究类型

介入性

注册 (估计的)

60

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Zhejiang
      • Hangzhou、Zhejiang、中国、310015
        • 招聘中
        • The Affiliated Hospital of Hangzhou Normal University
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Right-handed individuals.
  • Diagnosis of irritable bowel syndrome according to the Rome IV criteria.
  • Presence of depressive symptoms, defined as a HAMD-17 score greater than 7.
  • Inadequate response to at least two months of conventional treatment for IBS.
  • Ability to understand the study procedures and provide written informed consent.
  • Willingness and ability to undergo MRI examinations and complete the study assessments.

Exclusion Criteria:

  • Contraindications to MRI or transcranial magnetic stimulation.
  • Known food intolerance, relevant gastrointestinal surgery, or gastrointestinal diseases other than IBS that may explain the symptoms.
  • History of significant neurological disorders or psychiatric disorders other than the depressive symptoms under investigation.
  • History of intracranial surgery.
  • Intracranial mass lesions or severe white matter abnormalities detected by MRI.
  • Other conditions that, in the investigator's judgment, would make participation inappropriate or unsafe.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Active Individualized iTBS

Participants will receive individualized intermittent theta-burst stimulation targeting the left dorsolateral prefrontal cortex. The stimulation target will be identified using resting-state fMRI-guided functional connectivity analysis.

Stimulation will be delivered at 90% of the resting motor threshold, with 1,800 pulses per session. Each session will comprise three blocks of 600 pulses, separated by approximately 15-minute intervals. Participants will receive five sessions per week for two weeks, for a total of 10 sessions.

Resting-state fMRI-guided iTBS targeting the individualized left dorsolateral prefrontal cortex at 90% of resting motor threshold, delivering 1,800 pulses per session for 10 sessions over two weeks.

假比较器:Sham iTBS

Participants will undergo a sham stimulation procedure with a schedule comparable to the active intervention. The stimulation coil will be positioned at 90 degrees to minimize effective cortical stimulation.

Participants will receive five sessions per week for two weeks, for a total of 10 sessions.

A sham stimulation procedure using a coil positioned at 90 degrees, with a treatment schedule comparable to active iTBS.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change From Baseline in Depressive Symptom Severity Assessed by HAMD-17 at Week 2
大体时间:Baseline and end of Week 2

Depressive symptom severity will be assessed using the 17-item Hamilton Depression Rating Scale (HAMD-17). A higher score indicates greater depressive symptom severity. The change from baseline to the end of Week 2 will be compared between the active and sham stimulation groups.

Baseline and end of Week 2

次要结果测量

结果测量
措施说明
大体时间
Change From Baseline in IBS Symptom Severity at Week 2
大体时间:Baseline and end of Week 2

IBS symptom severity will be assessed using the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS). Changes from baseline to the end of Week 2 will be compared between groups.

Baseline and end of Week 2
Change From Baseline in Abdominal Pain Intensity at Week 2
大体时间:Baseline and end of Week 2

Abdominal pain intensity will be evaluated using a Visual Analog Scale (VAS).

Baseline and end of Week 2
Change From Baseline in Pain Severity Assessed by the Short-Form McGill Pain Questionnaire at Week 2
大体时间:Baseline and end of Week 2

Pain-related symptoms will be assessed using the Short-Form McGill Pain Questionnaire (SF-MPQ).

Baseline and end of Week 2
Change From Baseline in Anxiety Symptom Severity at Week 2
大体时间:Baseline and end of Week 2

Anxiety symptom severity will be assessed using the 14-item Hamilton Anxiety Rating Scale (HAMA-14).

Baseline and end of Week 2
Change From Baseline in IBS-Related Quality of Life at Week 2
大体时间:Baseline and end of Week 2

IBS-related quality of life will be assessed using the Irritable Bowel Syndrome Quality of Life questionnaire (IBS-QOL).

Baseline and end of Week 2
MRI Outcomes
大体时间:Baseline and end of Week 2

functional and structural brain network analyses

Baseline and end of Week 2
Safety Outcomes
大体时间:Baseline and end of Week 2

adverse-event incidence

Baseline and end of Week 2

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年12月1日

初级完成 (估计的)

2027年12月31日

研究完成 (估计的)

2027年12月31日

研究注册日期

首次提交

2026年11月10日

首先提交符合 QC 标准的

2026年11月10日

首次发布 (实际的)

2026年11月16日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅